Fund acquires 730,548 shares in Vir Biotechnology
Superstring Capital Management has established a new position in Vir Biotechnology, purchasing 730,548 shares in the first quarter. The estimated transaction value was $5.82 million based on quarterly average pricing.
The fund’s quarter-end position in Vir Biotechnology was valued at $6.55 million, reflecting both trading activity and price appreciation. Top holdings include $16.93 million in SMMT, $8.88 million in IMVT, and $8.67 million in COGT.
As of Friday, Vir Biotechnology shares were priced at $9.19, up 99% over the past year and outperforming the S&P 500, which is up about 28% in the same period.
Vir Biotechnology develops monoclonal antibodies and RNA-based therapeutics targeting infectious diseases, including COVID-19, hepatitis B, influenza A, and HIV.